{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:48:51Z","timestamp":1777380531454,"version":"3.51.4"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1097\/crd.0000000000000090","type":"journal-article","created":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T14:34:21Z","timestamp":1443105261000},"page":"224-229","source":"Crossref","is-referenced-by-count":6,"title":["The Use of Statins in the Treatment and Prevention of Atrial Fibrillation"],"prefix":"10.1097","volume":"24","author":[{"given":"Donald","family":"Groves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos G.","family":"Mihos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiteder","family":"Larrauri-Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlando","family":"Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210203","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/CRD.0b013e3181f52a7f","article-title":"The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review.","volume":"18","author":"Mihos","year":"2010","journal-title":"Cardiol Rev"},{"key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins.","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins.","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.phrs.2014.02.009","article-title":"Cardiovascular effects of statins, beyond lipid-lowering properties.","volume":"88","author":"Mihos","year":"2014","journal-title":"Pharmacol Res"},{"key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1161\/01.CIR.103.21.2598","article-title":"Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice.","volume":"103","author":"Scalia","year":"2001","journal-title":"Circulation"},{"key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/hq0202.104081","article-title":"Cellular antioxidant effects of atorvastatin in vitro and in vivo.","volume":"22","author":"Wassmann","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1096\/fj.05-5067fje","article-title":"Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits.","volume":"20","author":"M\u00fchlh\u00e4user","year":"2006","journal-title":"FASEB J"},{"key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cardiores.2004.01.018","article-title":"The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.","volume":"62","author":"Kumagai","year":"2004","journal-title":"Cardiovasc Res"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1755-5922.2009.00103.x","article-title":"Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.","volume":"28","author":"Li","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.amjcard.2009.12.011","article-title":"Differential effects of statins (pravastatin or simvastatin) on ventricular ectopic complexes: Galpha(i2), a possible molecular marker for ventricular irritability.","volume":"105","author":"Welzig","year":"2010","journal-title":"Am J Cardiol"},{"key":"R12-3-20210203","first-page":"e257","article-title":"ACC\/AHA\/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"125R","DOI":"10.1016\/S0002-9149(99)00712-2","article-title":"Mechanisms of atrial fibrillation and flutter and implications for management.","volume":"84","author":"Chen","year":"1999","journal-title":"Am J Cardiol"},{"key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.108.825380","article-title":"Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.","volume":"119","author":"Benjamin","year":"2009","journal-title":"Circulation"},{"key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.hrthm.2006.05.010","article-title":"Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.","volume":"3","author":"Hanna","year":"2006","journal-title":"Heart Rhythm"},{"key":"R16-3-20210203","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.amjcard.2003.08.040","article-title":"Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.","volume":"92","author":"Young-Xu","year":"2003","journal-title":"Am J Cardiol"},{"key":"R17-3-20210203","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1253\/circj.CJ-12-0722","article-title":"Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years\u2019 follow-up.","volume":"76","author":"Warita","year":"2012","journal-title":"Circ J"},{"key":"R18-3-20210203","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejphar.2013.03.012","article-title":"Statin therapy is beneficial for the prevention of atrial fibrillation in patients with coronary artery disease: a meta-analysis.","volume":"707","author":"Zhou","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011.","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"R20-3-20210203","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/eurheartj\/ehr460","article-title":"High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial.","volume":"33","author":"Pe\u00f1a","year":"2012","journal-title":"Eur Heart J"},{"key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/eurheartj\/ehp357","article-title":"Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial.","volume":"30","author":"Maggioni","year":"2009","journal-title":"Eur Heart J"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/europace\/eur016","article-title":"The incidence and risk factors for new onset atrial fibrillation in the PROSPER study.","volume":"13","author":"Macfarlane","year":"2011","journal-title":"Europace"},{"key":"R23-3-20210203","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.jacc.2009.08.020","article-title":"Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).","volume":"54","author":"Haywood","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ahj.2011.02.002","article-title":"High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.","volume":"161","author":"Schwartz","year":"2011","journal-title":"Am Heart J"},{"key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2125.2012.04258.x","article-title":"The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.","volume":"74","author":"Fang","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R26-3-20210203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/HCO.0b013e32835b0956","article-title":"Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials.","volume":"28","author":"Fauchier","year":"2013","journal-title":"Curr Opin Cardiol"},{"key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2261-14-99","article-title":"The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials.","volume":"14","author":"Yang","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"R28-3-20210203","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ahj.2005.06.032","article-title":"Effect of C-reactive protein reduction on paroxysmal atrial fibrillation.","volume":"150","author":"Dernellis","year":"2005","journal-title":"Am Heart J"},{"key":"R29-3-20210203","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.4238\/2013.September.10.5","article-title":"Effect of atorvastatin on left atrial function of patients with paroxysmal atrial fibrillation.","volume":"12","author":"Li","year":"2013","journal-title":"Genet Mol Res"},{"key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1253\/circj.CJ-09-0643","article-title":"Impact of drug alteration to maintain rhythm control in paroxysmal atrial fibrillation. Subanalysis from J-RHYTHM study.","volume":"74","author":"Endo","year":"2010","journal-title":"Circ J"},{"key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1536\/ihj.50.465","article-title":"Long-term efficacy of upstream therapy using angiotensin-converting enzyme inhibitors and statins in combination with antiarrhythmic agents for the treatment of paroxysmal atrial fibrillation.","volume":"50","author":"Komatsu","year":"2009","journal-title":"Int Heart J"},{"key":"R32-3-20210203","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.12659\/MSM.891049","article-title":"Statin therapy decreased the recurrence frequency of atrial fibrillation after electrical cardioversion: a meta-analysis.","volume":"20","author":"Yan","year":"2014","journal-title":"Med Sci Monit"},{"key":"R33-3-20210203","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1378\/chest.128.5.3421","article-title":"Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein.","volume":"128","author":"Amar","year":"2005","journal-title":"Chest"},{"key":"R34-3-20210203","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/CIRCULATIONAHA.106.621763","article-title":"Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.","volume":"114","author":"Patti","year":"2006","journal-title":"Circulation"},{"key":"R35-3-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2008.01.028","article-title":"Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial.","volume":"156","author":"Tsai","year":"2008","journal-title":"Am Heart J"},{"key":"R36-3-20210203","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/europace\/euq044","article-title":"Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review.","volume":"12","author":"Santangeli","year":"2010","journal-title":"Europace"},{"key":"R37-3-20210203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1074248414564869","article-title":"Atorvastatin reduces the incidence of postoperative atrial fibrillation in statin-naive patients undergoing isolated heart valve surgery: a double-blind, placebo-controlled randomized trial.","volume":"20","author":"Dehghani","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R38-3-20210203","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.amjcard.2011.03.028","article-title":"Effect of early statin therapy on risk of atrial fibrillation after coronary artery bypass grafting with or without concomitant valve surgery.","volume":"108","author":"Rader","year":"2011","journal-title":"Am J Cardiol"},{"key":"R39-3-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.hrthm.2011.09.003","article-title":"Statin use and postoperative atrial fibrillation after major noncardiac surgery.","volume":"9","author":"Bhave","year":"2012","journal-title":"Heart Rhythm"},{"key":"R40-3-20210203","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.hrthm.2011.09.016","article-title":"Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial.","volume":"9","author":"Suleiman","year":"2012","journal-title":"Heart Rhythm"},{"key":"R41-3-20210203","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.jvca.2014.08.013","article-title":"Preoperative statin therapy decreases early mortality in patients undergoing isolated valve surgery: result from a meta-analysis.","volume":"29","author":"Cheng","year":"2015","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R42-3-20210203","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.amjcard.2015.02.053","article-title":"Meta-analysis of 12 trials evaluating the effects of statins on decreasing atrial fibrillation after coronary artery bypass grafting.","volume":"115","author":"Elgendy","year":"2015","journal-title":"Am J Cardiol"},{"key":"R43-3-20210203","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.7326\/0003-4819-135-12-200112180-00010","article-title":"Atrial fibrillation after cardiac surgery.","volume":"135","author":"Maisel","year":"2001","journal-title":"Ann Intern Med"},{"key":"R45-3-20210203","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/ejcts\/ezt399","article-title":"Statins and long-term survival after isolated valve surgery: the importance of valve type, position and procedure.","volume":"45","author":"Pullan","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"R46-3-20210203","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1510\/icvts.2009.230060","article-title":"Statins improve surgical ablation outcomes for atrial fibrillation in patients undergoing concomitant cardiac surgery.","volume":"11","author":"Kuhn","year":"2010","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R47-3-20210203","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/01.CIR.0000057981.70380.45","article-title":"Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST).","volume":"107","author":"Glotzer","year":"2003","journal-title":"Circulation"},{"key":"R48-3-20210203","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.114.008201","article-title":"Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning.","volume":"129","author":"Patel","year":"2014","journal-title":"Circulation"},{"key":"R49-3-20210203","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials.","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"R50-3-20210203","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy.","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"R51-3-20210203","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","article-title":"Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.","volume":"33","author":"Chatzizisis","year":"2010","journal-title":"Drug Saf"},{"key":"R52-3-20210203","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/01.STR.0000131269.69502.d9","article-title":"Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack.","volume":"35","author":"Jabaudon","year":"2004","journal-title":"Stroke"},{"key":"R53-3-20210203","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.amjcard.2005.01.025","article-title":"Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour Holter monitors for arrhythmia detection.","volume":"95","author":"Reiffel","year":"2005","journal-title":"Am J Cardiol"},{"key":"R54-3-20210203","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"R55-3-20210203","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/14779072.1.4.495","article-title":"Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.","volume":"1","author":"Rosenson","year":"2003","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:49:58Z","timestamp":1620949798000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201609000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000090","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}